{
    "eid": "2-s2.0-85101145531",
    "title": "The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy",
    "cover-date": "2021-03-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology and Allergy",
            "@code": "2723",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cell Biology",
            "@code": "1307",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Transplantation",
            "@code": "2747",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Cellular therapy",
        "Chimeric antigen receptor T cells",
        "International Prognostic Index",
        "Non-Hodgkin lymphoma"
    ],
    "authors": [
        "Marta Garcia-Recio",
        "Kitsada Wudhikarn",
        "Martina Pennisi",
        "Rosalia Alonso-Trillo",
        "Jessica Flynn",
        "Roni Shouval",
        "Aishat O. Afuye",
        "Mari Lynne Silverberg",
        "Connie W. Batlevi",
        "Parastoo Dahi",
        "Sean Devlin",
        "Sergio A. Giralt",
        "Elizabeth Halton",
        "Josel Ruiz",
        "Molly Maloy",
        "Elena Mead",
        "M. Lia Palomba",
        "Bianca Santomasso",
        "Craig S. Sauter",
        "Michael Scordo",
        "Gunjan L. Shah",
        "Miguel Angel Perales"
    ],
    "citedby-count": 14,
    "ref-count": 50,
    "ref-list": [
        "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues",
        "Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment",
        "Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019 Etudes des Lymphomes de l'Adulte",
        "Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study",
        "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma",
        "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia",
        "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma",
        "Late events after treatment with CD19-targeted chimeric antigen receptor modified T-cells",
        "Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis",
        "Chimeric antigen receptor T\u2011cell therapy\u2014assessment and management of toxicities",
        "Cytokine release syndrome",
        "The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma",
        "Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management",
        "Diffuse large B-cell lymphoma",
        "A predictive model for aggressive non-Hodgkin's lymphoma",
        "Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma",
        "Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT",
        "Indications for autologous and allogeneic hematopoietic cell transplantation : guidelines from the American Society for Blood and Marrow Transplantation",
        "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation",
        "Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT",
        "The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma",
        "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells",
        "The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP",
        "Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+B-cell lymphoma in the rituximab era",
        "The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission",
        "Hematopoietic cell transplantation comorbidity index (HCT- CI) predicts outcomes in patients with acute myeloid leukemia and myelodysplastic syndromes receiving CD34+ selected grafts for allogeneic hematopoietic cell transplantation",
        "Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in nonmyeloablative allogeneic stem cell transplantation",
        "Hematopoietic cell transplantation-specific comorbidity index predicts morbidity and mortality in autologous stem cell transplantation",
        "Prognostic value of the Hematopoietic Cell Transplantation Comorbidity Index for patients undergoing reduced-intensity conditioning cord blood transplantation",
        "Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the",
        "Comparison of CAR-T19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma",
        "The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells",
        "Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity",
        "Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium",
        "Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy",
        "High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma",
        "A comparison of 2-year outcomes in ZUMA-1 (axicabtagene ciloleucel [Axi-Cel]) and SCHOLAR-1 in patients (Pts) with refractory large B cell lymphoma (LBCL)",
        "Risk factors and characteristics of CRS in CAR-T treatment",
        "Chimeric antigen receptor modified T cell therapy for B cell malignancies",
        "Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B-cell malignancies",
        "Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia",
        "Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy",
        "Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies",
        "Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy",
        "Endothelial activation and blood \u2013 brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells",
        "The lymphoma tumor microenvironment influences toxicity after CD19 CAR T cell therapy",
        "Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes [e-pub ahead of print]",
        "Real-world analysis of adverse events associated with CAR T-cell therapy among adults age \u226565 years",
        "Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy",
        "Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B cell lymphoma: a multicenter analysis [e-pub ahead of print]"
    ],
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Milan",
            "@id": "60030318",
            "affilname": "Universit\u00e0 degli Studi di Milano",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60030318",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Majadahonda",
            "@id": "60025844",
            "affilname": "Hospital Universitario Puerta de Hierro Majadahonda",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025844",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "New York",
            "@id": "60007997",
            "affilname": "Weill Cornell Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Milan",
            "@id": "60006583",
            "affilname": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milan",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006583",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Associazione italiana contro le leucemie-linfomi e mieloma Milano e Provincia ONLUS",
        "CIBMTR Cellular Immunotherapy Data Resource Committee",
        "GLG",
        "McKinsey & Company and Angiocrine Bioscience",
        "National Cancer Institute Cancer Center Support",
        "National Institutes of Health",
        "Amgen",
        "Bristol-Myers Squibb",
        "Astellas",
        "Merck",
        "Novartis",
        "American-Italian Cancer Foundation",
        "Abbvie",
        "Janssen",
        "Parker Institute of Cancer Immunotherapy",
        "Bayer",
        "American Society for Transplantation and Cellular Therapy",
        "Miltenyi Biotec"
    ]
}